Document |
Document Title |
WO/1983/004263A1 |
in vitro enzymatic processes which efficiently convert compounds containing a primary alcohol to their corresponding novel 0-glucuronic acid derivatives. Exemplified as starting compounds are anticholinergics containing a primary alcohol...
|
JP2024509776A |
The present invention relates to the isolation and purification of sialylated oligosaccharides from the aqueous medium in which they are produced. [Selection diagram] None
|
JP2024508368A |
The present invention relates to synthetic sialosides of formula (I). Neu5Ac-α2-6-R1(R2)[GlcNAcβ1-4]n-GlcNAc formula (where GlcNAc is N-acetylglucosamine, GlcNAcβ1-4 are N-acetylglucosamine units linked by β1-4 bonds, n is 1 or more,...
|
JP2024504135A |
The present invention provides the following formula (I): and methods for their preparation, in cosmetic or dermatological applications, in particular for the treatment and/or prevention of skin aging, skin protection or skin regeneratio...
|
JP2023554334A |
The present invention relates to a method for separating various oligosaccharides having at least one carboxylic acid group, also called charged oligosaccharides. This method allows high throughput separation of oligosaccharides that are...
|
JP2023553939A |
The present invention relates to the pentose intermediate of fondaparinux sodium, and is based on an automated device to realize automated production of the three components (D+EF+GH) through automatic sample loading, automatic sampling ...
|
JP2023526699A |
Compounds that inhibit sodium-glucose conjugate transporter 1, and pharmaceutically acceptable salts and stereoisomers thereof. The compounds are used in pharmaceutical compositions. Methods for the preparation and use of pharmaceutical ...
|
JP2023525663A |
The present invention relates to compounds and compositions that can be used to mask, block, or reduce, at least in part, the bitter taste present in various oral consumables. The present invention also relates to methods of using bitter...
|
JP7285048B2 |
To provide a method for obtaining a composition containing hyaluronic acid oligosaccharide which can be applied to an industrial scale.A production method includes: (A) a process of applying a decomposed product of hyaluronic acid and/or...
|
JP7282108B2 |
The present invention relates to the cosmetic use, as moisturizer for keratin materials, preferably the skin, of one or more 5-oxazolidine-2,4-dione C-glycoside derivatives corresponding to formula (I) below, and also the solvates and/or...
|
JP2023070184A |
To provide a novel thioester derivative and a method for producing the same, a novel ketone derivative and a method for producing the same, a novel method for producing a C-arylhydroxyglucoside derivative, and a novel method for producin...
|
JP7273997B2 |
Crystal form A of a compound represented by formula (I) and an application thereof in preparing a drug for treating an SGLT1/SGLT2-related disease.
|
JP7267675B2 |
An object of the present invention is to provide a crystal of 6'-sialyllactose (hereinafter, referred to as 6SL) sodium salt, which is easily handled, and has high storage stability at normal temperature as well as under high temperature...
|
JP7245966B2 |
To provide a sphingosine derivative that exhibits AGEs adsorbing action.A sphingosine derivative is an amphipathic compound constituted of sphingosine, dicarboxylic acid pyridine and guluronic acid. A method for producing the derivative ...
|
JP7198210B2 |
The present invention is directed to a polymer of Formula (IV):wherein A, X, Q, Y, Z, m1, m2, m3, k1, and k2 are as described herein and wherein the monomer units of the polymer are the same or different. The present invention also relat...
|
JP7166450B2 |
A fucosylated chondroitin sulfate oligosaccharide having the structure as shown in J, and further disclosed is a method for preparing the fucosylated chondroitin sulfate oligosaccharide: using a chondroitin sulfate A salt as a raw materi...
|
JP2022542815A |
Due to its ability to increase lipid synthesis, the present invention provides skin swelling and/or skin volumization and/or skin densification and/or wrinkle filling and/or skin or hair moisturizing and/or skin or hair hydration. Glycop...
|
JP2022535733A |
Found herein is a process for the preparation of calcium, magnesium and zinc salts of sugar acids, which is an object of the present invention, the process comprising providing a sugar, a noble metal catalyst, oxygen, and oxidizing sugar...
|
JP2022069548A |
To provide: crystals of 6'-sialyl lactose (hereinafter referred to as 6SL) that are easy to handle and have high storage stability under normal temperature and high temperature conditions; and a method for producing the crystals.The pres...
|
JP2022068297A |
To provide compounds for treating Filoviridae virus infections, and methods for preparing pharmaceutical compositions.The invention provides a compound for treating Filoviridae virus infection, and a method for preparing a pharmaceutical...
|
JP2022502393A |
N-(1-((2- (dimethylamino) ethyl) amino) -2-methyl-1-oxopropan-2-yl) -4- (4- (2-methyl-5-((2S, 3R,,) 4R, 5S, 6R) -3,4,5-trihydroxy-6- (methylthio) tetrahydro-2H-pyran-2-yl) benzyl) phenyl) butaneamide and its salts, admixtures and co-crys...
|
JP6977059B2 |
The present invention relates to a mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m' ...
|
JP6965274B2 |
Disclosed are an amine solvate of a sodium-glucose linked transporter (SGLT) inhibitor, and a preparation method and application thereof. The SGLT inhibitor is (1 S ,2 S ,3 S ,4 R ,5 S )-5-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)...
|
JP2021516248A |
The present invention relates to the field of pharmaceutical synthesis, in particular to methods for preparing (3R, 3aS, 6aR) -hexahydroflo [2,3-b] furan-3-ol derivatives and their intermediates. The above preparation method is carried o...
|
JP6867806B2 |
According to the present invention, a crystal of an alkali metal N-acetylneuraminate anhydrate, and a process for producing a crystal of an alkali metal N-acetylneuraminate anhydrate, comprising adding or adding dropwise a solvent select...
|
JP6851379B2 |
The present invention relates to an improved crystallization procedure to obtain canagliflozin hemihydrate crystals having a narrow particle size distribution by removing a small part of the crystalline suspension in the crystallization ...
|
JP6846509B2 |
The invention relates to a new method of preparing oligomannuronic diacids, important bioactives. The method utilizes oligomannuronic acids as starting materials and the target substances are obtained by acid degradation and active hypob...
|
JP2021036002A |
To provide: crystals of 6'-sialyl lactose (hereinafter referred to as 6SL) that are easy to handle and have high storage stability under normal temperature and high temperature conditions; and a method for producing the crystals.The pres...
|
JP2021506962A |
To synthesize a 1: 1: 1 co-crystal composed of 1-cyano-2- (4-cyclopropyl-benzyl) -4- (β-D-glucopyranos-1-yl) -benzene, L-proline and water. Provide the law. According to the present invention, (a) the final intermediate (FT) is deacetyl...
|
JP6813028B2 |
It is an object of the present invention to provide a pattern forming method capable of easily forming a phase-separated structure with high accuracy, even in the case of widening the applicable range of a pattern size. The present inven...
|
JP2020534361A |
The compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed herein. [Chemical 1] The variables in formula (I) are described herein. Methods for synthesizing such compounds, as well as for treating diseases an...
|
JP6751838B2 |
To provide a neuraminic acid derivative exhibiting Langerhans cell-activating action and a method for producing the same.According to the invention, a neuraminic acid derivative of interest is a derivative consisting of one molecule of n...
|
JP6737691B2 |
The invention provides compositions and methods for engineering bacteria to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.
|
JP6727419B2 |
The present disclosure relates to novel crystalline forms of a sodium-glucose co-transporter inhibitor drug (Sotagliflozin), processes for preparation and use thereof. The present disclosure also relates to pharmaceutical composition com...
|
JP2020073543A |
To provide compounds and methods for treating and preventing bacterial infections, specifically, urinary tract infections and infections caused by bacteria containing type 1 pili and FimH.The invention provides the compound illustrated b...
|
JP6671305B2 |
According to the present invention, a crystal of ammonium N-acetylneuraminate anhydrate, and a process for producing a crystal of ammonium N-acetylneuraminate anhydrate, comprising adding or adding dropwise a solvent selected from the gr...
|
JP6666243B2 |
The present application discloses a process for the purification of 2'-fucosyllactose produced by fermentation, enzymatic synthesis or chemical synthesis or combinations thereof. The process uses simulated moving bed (SMB) chromatography...
|
JP6629285B2 |
The present invention relates also to uses thereof for preservation and/or protection and/or regeneration of biological materials and or microorganisms and for cosmetic or dermatological applications such as anti-aging, skin protection a...
|
JP6605201B2 |
|
JP2019530722A |
The present invention relates to the general formula III (in the formula, R).1, R2, And R'with respect to the method for preparing a glucopyranosyl-substituted benzylbenzene derivative (as defined by claim 1), and the use of such method ...
|
JP6591398B2 |
Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an ...
|
JP2019520342A |
The present invention describes a novel conjugate of a drug and part of formula (I) that can bind to a glucose-sensing protein that allows the reversible release of the drug depending on the glucose concentration.
|
JP2019048901A |
To provide compounds for treating Filoviridae virus infections, and methods for preparing pharmaceutical compositions.The invention provides a compound for treating Filoviridae virus infection, and a method for preparing a pharmaceutical...
|
JP6455857B2 |
|
JP2018139587A |
To provide a method for producing one product from one or more enzymatic pathways.According to the present invention, there is provided a method comprising both enzymatic and chemical conversions as steps. According to the present invent...
|
JP6353054B2 |
The present invention relates to C-aryl glucoside derivative, a preparation method for same, and medical applications thereof. Specifically, the present invention relates to compounds as represented by formula I, and, tautomers, enantiom...
|
JP6302909B2 |
Provided herein are compounds for use as sialidase inhibitors, including alkynyl-3-fluorosialyl fluoride. The compounds, which include the compound DFSA, function by trapping a 3-fluorosialylenzyme intermediate (reporter-inhibitor-enzyme...
|
JP2018024882A |
To provide a material and a method for conjugating a water-soluble polymer with a carbohydrate-containing compound other than a blood coagulation protein, improving pharmacodynamic and/or pharmacokinetic properties of the compound while ...
|
JP2017195885A |
To provide a method for producing one product from one or more enzymatic pathways.According to the present invention, there is provided a method comprising both enzymatic and chemical conversions as steps. According to the present invent...
|
JP6208745B2 |
Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter (SGLT) and synthetic intermediates useful for preparing such compounds.
|